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Abstract 
Aims: Cancer-related fatigue (CRF) is often accompanied by depressed mood, 
both of which reduce functional status and quality of life. Research suggests 
that increased expression of pro-inflammatory cytokines is associated with 
skeletal muscle wasting and depressive- and fatigue-like behaviors in rodents 
and cancer patients. We have previously shown that treatment with 
ibuprofen, a nonsteroidal anti-inflammatory drug, preserved muscle mass in 
tumor-bearing mice. Therefore, the purpose of the present study was to 
determine the behavioral effects of ibuprofen in a mouse model of CRF. 
Main methods: Mice were injected with colon-26 adenocarcinoma cells and 
treated with ibuprofen (10 mg/kg) in the drinking water. Depressive-like 
behavior was determined using the forced swim test (FST). Fatigue-like 
behaviors were determined using voluntary wheel running activity (VWRA) 
and grip strength. The hippocampus, gastrocnemius muscle, and serum were 
collected for cytokine analysis. 
Key findings: Tumor-bearing mice showed depressive-like behavior in the 
FST, which was not observed in mice treated with ibuprofen. VWRA and grip 
strength declined in tumor-bearing mice, and ibuprofen attenuated this 
decline. Tumor-bearing mice had decreased gastrocnemius muscle mass and 
increased expression of IL-6, MAFBx and MuRF mRNA, biomarkers of protein 
degradation, in the muscle. Expression of IL-1β and IL-6 was also increased 
in the hippocampus. Treatment with ibuprofen improved muscle mass and 
reduced cytokine expression in both the muscle and hippocampus of tumor-
bearing mice. 
Significance: Ibuprofen treatment reduced skeletal muscle wasting, 
inflammation in the brain, and fatigue- and depressive-like behavior in tumor-
bearing mice. Therefore, ibuprofen warrants evaluation as an adjuvant 
treatment for CRF. 
 
Keywords: Fatigue, Depression, Cancer, Neuroinflammation, Ibuprofen 
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1. Introduction 
Fatigue is a common and disabling side effect of cancer and 
cancer therapies. Cancer related fatigue (CRF) significantly reduces 
quality of life1,2,3,4 and is frequently associated with depressed 
mood.5,6,7  The mechanism for this association is unclear and is 
relevant for development of effective treatments to reduce fatigue and 
depression in cancer survivors.1  
In response to tumor growth, increased expression of immune 
mediators leads to systemic inflammation throughout the host.8  In 
skeletal muscle, pro-inflammatory cytokines activate NF-κB, which 
increases expression of proteins involved in muscle degradation, 
including MAFbx and MuRF1.9,10  Tumor-bearing mice develop 
extensive loss of muscle mass and show functional impairments such 
as decreased grip strength11,12,13 and reduced voluntary wheel running 
activity (VWRA).11  Fatigue is often the presenting complaint of newly 
diagnosed cancer patients and sarcopenia can be present at the time 
of diagnosis.14  
Increased expression of pro-inflammatory cytokines is also 
associated with depressed mood.15 In animal models of CRF, tumor 
growth has been shown to increase inflammation within the brain.11,16 
This is important because increases in brain interleukin (IL)-1β are 
linked to both muscle atrophy17 and depressed mood11,15 in mice. In 
addition, evidence from rodent models indicates that inflammatory 
cytokines within the CNS are associated with behavioral symptoms of 
fatigue, such as decreased VWRA activity.11,18,19 
Inflammatory cytokines increase prostaglandin synthesis, an 
important mediator of the inflammatory response. Common 
nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, 
decrease prostaglandin synthesis by inhibiting the cyclo-oxygenase 
(COX) enzymes and nitric oxide (NO).20 Ibuprofen has been shown to 
decrease depressive-like behavior in a mouse model of bacterial 
infection,21 and a recent clinical report showed decreased depression 
scores in osteoarthritis patients treated with ibuprofen.22 Treatment 
with NSAIDs has been shown to reduce skeletal muscle wasting in 
tumor-bearing mice23,24,25 and to improve grip strength and 
performance status in cancer patients treated with ibuprofen.26 
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However, the effects of ibuprofen or other NSAIDs on CRF have not 
been studied. Here, we examined the effects of ibuprofen on 
depressive and fatigue-like behaviors in a mouse model of CRF. Using 
this model, we have previously shown that tumor growth is associated 
with increased muscle and brain expression of IL-1β and IL-6 mRNA, 
increased serum levels of IL-6, skeletal muscle wasting and weakness, 
and the development of fatigue- and depressive-like behaviors.11,27,28  
2. Materials and methods 
2.1. Mice 
Adult (10 weeks) female BALB/c x DBA/2F1 (CD2F1) mice 
weighing 20–22 g were obtained from Charles River Laboratories. 
Female mice were used because we and others have shown that 
tumor-bearing females maintain their food intake and lose a smaller 
percent of body mass than male mice29 and male mice tend to gnaw 
and bite at the tumor site, causing local inflammation.30 Mice were 
singly housed and maintained at 25 °C under a 12 h light cycle with ad 
libitum access to water and rodent chow. All procedures were 
performed in accordance with the National Institute of Health 
Guidelines for the Care and Use of Laboratory Animals and were 
approved by The Ohio State University Institutional Animal Care and 
Use Committee. 
2.2. Mouse model of tumor-growth 
The colon-26 adenocarcinoma (C26) cell line was maintained in 
culture and prepared for injection as previously described.27,31 Half the 
mice were injected subcutaneously between the scapulae with 5 × 105 
cells in 0.2 ml of PBS, and half served as healthy controls with PBS 
injection alone. This tumor cell line is syngeneic for CD2F1 mice and 
secretes IL-6 and TNF-α25 and does not metastasize when injected 
subcutaneously.32 Tumor growth is usually palpable by day 7, weight 
loss, splenomegaly, and muscle wasting are evident after day 14, and 
mice become moribund by day 24 of tumor-growth. In the present 
study, all data collection was completed by day 21 of tumor growth. 
Body weight was monitored three times a week for the first two 
weeks, and daily during the third week. Mice were euthanized by 
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inhalation of CO2 gas on day 21 of tumor growth. Gastrocnemius 
muscles, spleen, and tumor were dissected and weighed; the brain 
was quickly dissected and hippocampus brain tissue was snap frozen in 
liquid nitrogen. Gastrocnemius weights were averaged and were 
normalized to body weight. At the time of sacrifice, 3 tumor-vehicle 
and 3 tumor-ibuprofen mice were removed from the study because 
there was no tumor growth established. 
2.3. Oral ibuprofen administration 
Ibuprofen sodium salt (Sigma, St. Louis) was dissolved at 
50 mg per liter (0.05 mg/mL) of filtered drinking water. Ibuprofen was 
then administered in the drinking water of half the tumor-bearing and 
half the healthy control mice starting three days after injection of PBS 
or tumor cells. Based on water consumption of 4 mL per day, this 
gives a dose of 10 mg/kg/day ibuprofen. A dose of 5 mg/kg has 
previously been shown to decrease muscle wasting in C26 tumor-
bearing mice23 and a dose of 40 mg/kg has been shown to suppress 
depressive-like behavior in mice inoculated with Bacillus Calmette–
Guerin (BCG).21  All other animals received water only (vehicle). Water 
bottles were changed weekly throughout the study. 
2.4. Voluntary wheel running activity 
Fatigue-like behavior was modeled as decreased voluntary 
wheel running activity (VWRA).33 Mice were singly housed and 
acclimated to a four inch diameter running wheel in the cage for one 
week, and baseline measures (week 0) of VWRA were recorded 
overnight prior to injection with tumor cells or PBS. Wheels were again 
placed in the home cages of all mice overnight (6 p.m. to 8 a.m.) on 
days 7 (week 1), 14 (week 2) and 20 (week 3) of tumor growth and 
the total number of turns each night was digitally recorded (Columbus 
Instruments, model 0297-004M). Data are expressed as a percentage 
of baseline. 
2.5. Grip strength measurements 
Forelimb grip strength was determined as previously 
described.34 In brief, each mouse was allowed to grasp a platform with 
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both forelimbs and was pulled by the tail until it released itself from 
the platform (Columbus Instruments, model 1027DSM). Peak force 
measurements (N) were recorded in five trials and the average was 
calculated. Because smaller mice have smaller grip strength, peak 
force was normalized to body weight of the animal. 
2.6. Depressive-like behavior 
Depressive-like behavior was determined on day 13 using the 
forced swim test (FST) as described previously.35 In the FST, mice 
were placed in an inescapable cylinder (diameter 16 cm, height 30 cm) 
containing 15 cm of water and behavior was recorded for 5 min. The 
latency to become immobile and the duration of immobility were 
determined. 
2.7. RNA isolation and RT-PCR analysis 
Total RNA was isolated from hippocampus brain sections using 
the Tri-Reagent protocol (Sigma) and reverse transcribed to cDNA 
using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). Quantitative PCR was performed using the Applied 
Biosystems Assay-on-Demand Gene Expression protocol. In brief, 
experimental cDNA was amplified with an ABI PRISM 7300-sequence 
detection system (Applied Biosystems) by real-time PCR and 
normalized based on reference cDNA (GAPDH). RNA was isolated from 
the gastrocnemius muscle using a TissueLyser system in TRIzol 
Reagent. RNA was extracted and purified using RNeasy spin column 
purification (Qiagen, Valencia, CA.). RNA was reverse transcribed 
using iScript Reverse Transcription Supermix (Bio-Rad, 175 Hercules, 
CA) and quantitative PCR was performed using a three-step protocol 
on the CFX96 Real 176 Time System (Bio-Rad), as described 
previously.27 Briefly, cDNA was amplified using real time qPCR and was 
normalized based on reference cDNA (GAPDH). All data were analyzed 
with the comparative threshold cycle method. Data is expressed as 
fold change from control-vehicle. 
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2.8. Statistical analyses 
Data were subjected to a Shapiro–Wilk test using Statistical 
Analysis Systems (SAS) software (Cary, NC). Data were analyzed 
using two-way ANOVA (tumor, drug) using the General Linear Model 
procedures of SAS. When significant main or interaction effects were 
found, post hoc analyses for differences between group means were 
evaluated with the Least-Significant Difference procedure of SAS. All 
data are expressed as treatment means ± standard error of the mean 
(SEM). 
3. Results 
3.1. Ibuprofen ameliorated fatigue- and depressive-like 
behaviors in tumor-bearing mice 
Half the tumor-bearing and half the healthy control mice 
received water (vehicle) or water containing ibuprofen starting three 
days after tumor cell inoculation until study completion. Depressive-
like behavior was determined at 13 days after tumor cell inoculation 
using the forced swim test (FST). There was a main effect of ibuprofen 
on time immobile (F1,38 = 7.64, p < 0.01), but no main effect of tumor. 
As shown in Fig. 1A, tumor-bearing mice given water only (vehicle) 
had increased total time immobile in the FST (p < 0.02), compared to 
healthy control mice. Tumor-bearing mice treated with ibuprofen, 
however, did not differ from control mice in total time immobile during 
the FST. These data suggest ibuprofen mitigated depressive-like 
behavior in the tumor-bearing mice. 
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Fig. 1. Ibuprofen ameliorated fatigue- and depressive-like behaviors in tumor-bearing 
mice. Control and tumor-bearing mice were treated with ibuprofen (10 mg/kg/day) in 
the drinking water. A) Immobility in the forced swim test (FST) was determined on 
day 13 of tumor growth. B) Voluntary wheel running activity (VWRA) was determined 
before tumor cell injection and again at days 7, 14, and 20. Data are expressed as 
percentage of baseline. Data were analyzed using two-way ANOVA and post hoc t-
tests for significant main effects: *p < 0.05 from control-vehicle, #p < 0.05 from 
tumor-vehicle. 
Fatigue-like behavior was determined using voluntary wheel 
running activity (VWRA)33 prior to tumor cell inoculation and again at 
7, 14, and 20 days of tumor growth. There was a main effect of tumor, 
but not ibuprofen, on VWRA on day 20 (F1,43 = 13.78, p < 0.01) (Fig. 
1B). Post hoc tests revealed that VWRA of vehicle treated tumor-
bearing mice was significantly decreased compared to vehicle-treated 
control mice (p < 0.02). VWRA of tumor-bearing mice treated with 
ibuprofen, however, was not significantly different from vehicle-treated 
control mice (p = 0.09). These data suggest that ibuprofen blunted the 
decline in VWRA in tumor-bearing mice. 
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3.2. Ibuprofen improved grip strength in tumor-bearing 
mice 
Forelimb grip strength was determined prior to tumor cell 
inoculation (week 0) and at 12 days and 19 days of tumor growth. Fig. 
2A shows the absolute grip strength and Fig. 2B shows the grip 
strength normalized to body weight. There was a main effect of tumor 
growth on absolute grip strength at 19 days (F1,38 = 48.99, p < 0.01) 
and a main effect of ibuprofen (F1,38 = 16.3, p < 0.01). Grip strength 
of both vehicle and ibuprofen treated tumor-bearing mice was 
decreased compared to control mice (p < 0.02). Grip strength in 
tumor-bearing mice treated with ibuprofen, however, was greater than 
vehicle treated tumor mice (p < 0.001). As shown in Fig. 2B, 
normalized grip strength of vehicle treated tumor-bearing mice was 
decreased compared to control mice (p < 0.001). Normalized grip 
strength in tumor-bearing mice treated with ibuprofen, however was 
not different from control mice (p = 0.11), indicating that ibuprofen 
blunted the decline in grip strength in tumor-bearing mice. 
 
Fig. 2. Ibuprofen restored grip strength in tumor-bearing mice. Control and tumor-
bearing mice were treated with ibuprofen (10 mg/kg/day) in the drinking water. A) 
Absolute grip strength was determined before tumor cell injection and again at day 11 
and 19. B) At day 20, grip strength was normalized to body weight. Data were 
analyzed using two-way ANOVA and post hoc t-tests for significant main effects: 
*p < 0.05 from control-vehicle, #p < 0.05 from tumor-vehicle. 
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3.3. Ibuprofen decreased systemic inflammation in 
tumor-bearing mice 
After completion of behavioral testing on day 21, mice were 
weighed, euthanized, and tumor, gastrocnemius, spleen, and brain 
were collected. Tumor-bearing mice had increased spleen weight 
(F1,38 = 87.49, p < 0.01), a nonspecific measure of systemic 
inflammation induced by tumor growth.36 There was an interaction 
between tumor and ibuprofen on spleen weight (F1,38 = 5.85, 
p < 0.02). As shown in Fig. 3A, ibuprofen treatment reduced spleen 
weight in the tumor-bearing mice (p < 0.003), although it remained 
significantly greater than in control animals (p < 0.001). Tumor-
bearing mice also had increased plasma levels of IL-6 compared to 
control animals (F1,25 = 14.37, p < 0.002). Ibuprofen tended to reduce 
plasma IL-6 in tumor-bearing mice, though the difference between 
tumor groups was not significant (p = 0.1) (Fig. 3B). As shown in Fig. 
3C, tumor weight tended to be lower in ibuprofen treated mice, 
although the difference was not significant (p = 0.3). 
 
Fig. 3. Ibuprofen decreased systemic inflammation and muscle wasting in tumor-
bearing mice. Control and tumor-bearing mice were treated with ibuprofen 
(10 mg/kg/day) in the drinking water. A) Spleen weight, B) plasma IL-6, C) tumor 
mass, and D) gastrocnemius muscle mass was determined at day 21. Gastrocnemius 
mRNA expression of E) MuRF, F) MAFBx, and G) IL-6 mRNA expression was 
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determined at day 21. Data were analyzed using two-way ANOVA and post hoc t-tests 
for significant main effects: *p < 0.05 from control-vehicle, #p < 0.05 from tumor-
vehicle. 
3.4. Ibuprofen reduced muscle wasting in tumor-
bearing mice 
There was a main effect of tumor growth on the relative 
gastrocnemius muscle mass (F1,38 = 18.40, p < 0.001), and an 
interaction effect of ibuprofen and tumor on muscle mass (F1,38 = 5.16, 
p < 0.03). Post hoc analyses demonstrated that relative muscle mass 
was decreased in tumor-bearing mice (p < 0.01) but that muscle mass 
of tumor-bearing mice treated with ibuprofen was not different from 
controls, consistent with our previous study23 (Fig. 3D). Because 
ibuprofen preserved gastrocnemius muscle mass in the tumor-bearing 
mice, we next determined mRNA expression of MuRF and MAFBx, 
biomarkers of protein degradation, in the muscle. There was a main 
effect of tumor on mRNA expression of MuRF (F1,38 = 6.94, p < 0.01). 
However, post hoc analyses showed that MuRF expression in tumor-
bearing mice treated with ibuprofen was not different from control 
mice (Fig. 3E). Similar to MuRF, there was a main effect of tumor 
growth on mRNA expression of MAFBx (F1,38 = 6.28, p < 0.02). Post 
hoc analyses showed that only the tumor-vehicle treated group, and 
not the tumor-ibuprofen treated group, was significantly different from 
controls (p < 0.006) (Fig. 3F). Thus, ibuprofen mitigated the effect of 
tumor growth on muscle expression of MuRF and MAFBx, as previously 
reported.23,24,25 Similarly, IL-6 mRNA expression was increased in 
muscle of tumor-bearing mice (F1,38 = 13.97, p < 0.001), but there 
was no significant effect of ibuprofen treatment (Fig. 3G). These data 
indicate that ibuprofen treatment abrogated expression of MAFBx and 
MuRF, biomarkers of muscle degradation in gastrocnemius muscle of 
tumor-bearing mice, and this was associated with decreased muscle 
wasting. 
3.5. Ibuprofen attenuated neuroinflammation in tumor-
bearing mice 
We have previously shown that tumor growth increased IL-1β 
and IL-6 mRNA expression in the brain at 2 weeks of tumor growth 
and that expression levels were further increased by 3 weeks.11 In the 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Life Sciences, Vol 143 (December 2015): pg. 65-70. DOI. This article is © Elsevier and permission has been granted for this 
version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Elsevier. 
12 
 
present study, tumor-bearing mice had increased expression of IL-1β 
(F1,45 = 13.06, p < 0.01) and IL-6 (F1,45 = 5.83, p < 0.02) mRNA in 
the hippocampus compared to controls at day 21 (Fig. 4A & B). There 
was also a main effect of ibuprofen on IL-1β expression (F1,45 = 4.68, 
p < 0.04), but there was no main effect of ibuprofen on IL-6 
expression (p = 0.08). However, there was an interaction effect of 
ibuprofen on IL-6 mRNA expression in the hippocampus of tumor-
bearing animals (F1,45 = 8.1, p < 0.01). These data suggest that 
ibuprofen reduced expression of IL-1β in both tumor-bearing and 
control mice, but selectively decreased IL-6 expression in the tumor-
bearing animals. Post hoc tests revealed that mRNA expression of IL-
1β in the tumor-vehicle mice was greater than in healthy controls, 
while expression levels in the tumor-ibuprofen mice was not different 
from controls and was significantly lower than the tumor-vehicle mice 
(p < 0.02). Similarly, expression of IL-6 mRNA in the untreated tumor 
mice was greater than in controls, and expression in the ibuprofen 
treated tumor mice was not different from controls. Thus, ibuprofen 
reduced neuroinflammation in the tumor-bearing mice. 
 
Fig. 4. Ibuprofen attenuated neuroinflammation in tumor-bearing mice. Control and 
tumor-bearing mice were treated with ibuprofen (10 mg/kg/day) in the drinking water. 
On day 21, the brain was collected and the hippocampus was dissected. A) IL-1β and 
B) IL-6 mRNA expression was determined. Data were analyzed using two-way ANOVA 
and post hoc t-tests for significant main effects: *p < 0.05 from control-vehicle, 
#p < 0.05 from tumor-vehicle. 
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4. Discussion 
Many cancer patients suffer with a constellation of symptoms 
termed cancer-related fatigue (CRF) which significantly impacts their 
quality of life.37,38 To date, there are no effective therapies for CRF. 
Moreover, CRF is often associated with depressed mood which also 
lowers quality of life and increases morbidity and mortality in cancer 
survivors.39,40 Both conditions are associated with increased expression 
of pro-inflammatory cytokines.1,8,15,16 In the present study, we used a 
mouse model of CRF in which tumor-bearing mice had increased 
plasma levels of IL-6, depressive-like behaviors in the forced swim 
test, decreased VWRA, and decreased muscle mass and grip strength. 
Ibuprofen treatment reduced muscle wasting and inflammation within 
the hippocampus of tumor-bearing mice. This is significant as the 
hippocampus is a brain region involved in both mood and cognition.41 
As a result, both fatigue- and depressive-like behaviors were 
attenuated in the tumor-bearing mice treated with ibuprofen. 
In our study, tumor-bearing mice had elevated levels of IL-6 in 
the plasma. Mice treated with ibuprofen tended to have decreased 
levels of IL-6 compared to vehicle treated mice, although IL-6 levels 
remained elevated compared to control mice. These data suggest that 
ibuprofen attenuated, but did not prevent, systemic inflammation, 
compared to control mice. This observation is supported by the 
increased spleen mass in tumor-bearing animals that was reduced by 
treatment with ibuprofen, although spleen mass remained greater than 
healthy control animals. It is possible that a higher dose of ibuprofen, 
or different NSAIDs might further reduce systemic inflammation in the 
tumor-bearing mice. 
Pro-inflammatory cytokines increase expression of biomarkers 
of autophagy and muscle protein degradation within muscle tissue, 
which likely contributes to the loss of muscle mass and grip strength in 
the tumor-bearing mice.9,42 We have previously shown that NSAID 
treatment can reduce expression of mediators of degradation, such as 
MAFBx and MuRF1, and reduce muscle wasting in tumor-bearing 
mice.23,24,25 Here, we confirm that ibuprofen treatment abrogated 
expression of MAFBx and MuRF mRNA in the muscle of in tumor-
bearing mice. However, we did not find that ibuprofen reduced 
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expression of IL-6 in muscle tissue, again raising the question of dose 
or alternative anti-inflammatory agents on tumor-induced muscle 
wasting. It is also possible that muscle IL-6 does not play a major role 
in muscle wasting. More importantly, the preservation of muscle mass 
was associated with improved grip strength and a smaller decline in 
VWRA in the tumor-bearing mice treated with ibuprofen. 
In addition to their peripheral effects, tumor-induced cytokines 
can activate the brain resident immune cells, microglia, which can 
further propagate these inflammatory signals throughout the central 
nervous system (CNS). This is critical as we have previously shown 
that increased inflammation in the brains of tumor-bearing mice is 
associated with both fatigue- and depressive like behaviors.19 
Administration of minocycline, a broad spectrum antibiotic with anti-
inflammatory capacity, inhibited microglial activation in tumor-bearing 
mice which resulted in reduced neuroinflammation and reduced 
depressive-like behavior in tumor-bearing mice.11 Furthermore, 
increased neuroinflammation is thought to induce depressive-like 
behavior via increased activity of IDO and KMO, which may reduce 
serotonin synthesis and availability in the brain.43,44 For example, we 
have previously shown that treatment with the SSRI Fluoxetine 
ameliorated depressive-like behavior in tumor bearing mice.19 Here we 
show that ibuprofen decreased IL-1β and IL-6 mRNA expression in the 
hippocampus of tumor-bearing mice to levels seen in healthy control 
mice. Further research using methods such as microdialysis is needed 
to determine if ibuprofen also restored serotonin levels in the 
cerebrospinal fluid of treated versus untreated tumor-bearing mice. 
Overall, the reduction in inflammation within the brains of tumor-
bearing mice treated with ibuprofen was associated with reduced 
depressive-like behaviors determined using the forced swim test. 
These data support other studies demonstrating that ibuprofen 
reduces depressive mood associated with inflammatory conditions.21,22  
In the present study, fatigue was modeled as reduced 
VWRA.33,45 We demonstrated that ibuprofen treatment tended to 
decrease this fatigue behavior in tumor-bearing mice. CRF may also 
involve muscle weakness, which was modeled as decreased grip 
strength. However, we have previously shown that grip strength can 
be improved without improvement in muscle mass.11 Therefore, in the 
present study, it is possible that improvement in these fatigue 
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behaviors may have been influenced by both the reduction in 
depressed mood and the rescue in muscle mass with ibuprofen 
treatment. 
In conclusion, we show beneficial effects of ibuprofen treatment 
on skeletal muscle mass and fatigue- and depressive-like behaviors in 
this mouse model of CRF. Previous clinical studies have shown 
prolonged survival46 and improved grip strength and performance 
status in cancer patients treated with NSAIDs.26 Our findings 
presented here suggest that NSAID treatment could have beneficial 
effects on muscle mass, physical performance, and mood of persons 
with CRF. 
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